SHANGHAI and SAN DIEGO and NAGANO, Japan, Aug. 5, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") and Kissei Pharmaceutical Co., Ltd. ("Kissei") announced today that they have entered into an exclusive license agreement for the development and commercialization of fostamatinib in mainland China, Hong Kong and Macau.
Search / 138 results found Showing: 1-10 of 138
Clinical Protocols based on Molecular Cancer genetics and DNA OncoPharmaceutics to detect aberrant cellular malformations induced by DNA methylation and histone modification in the cell nucleus of the mitotic spindle and microtubule chromosomal interface to disable cancer cell replication and proliferation
SAN FRANCISCO, Aug. 4, 2021 /PRNewswire/ -- Nathan Sassover, CEO of World Cancer Institute Inc. today stated: We are presenting further clinical guidance on the progression of the multivalent CancerVX / OncoVacx combinatorial therapeutic platform:
MIAMI, Aug. 4, 2021 /PRNewswire/ -- This week, the Heal the Earth Foundation continues to progress with its "Rx for Cuba" tour. Thanks to the capital raised at the first two shows, the foundation was able to purchase Ibuprofen in bulk to send to Cuba. While packing the bags with the Ibuprofen, Dr. Farshchian said, "It's unfortunate that we physically have to bring this medicine by hand to Cuba because of the lack of shipping services into the country and the concern that the Cuban government will take the luggage away if we check in the bag. So we fly to Cuba with the medicine as a carry-on." These bags are being flown into Cuba by a Heal the Earth representative. They are hand-delivered to ensure they are given to the right people. The products, in this case Ibuprofen, will be given directly to the people in need. Kristen Carranza, the Associate Director of Heal the Earth, said, "Having these bags packed with medicine so quickly after our first couple of shows makes me optimistic for the future fundraising we have planned. We are making a huge effort to help people in need, and I'm so glad to see the progress we've been making thus far."
PALO ALTO, Calif., Aug. 4, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that on August 3, 2021, the compensation committee of BridgeBio's board of directors granted 17 new employees restricted stock units for an aggregate of 21,414 shares of the Company's common stock. All of the above-described awards were made under BridgeBio's 2019 Inducement Equity Plan (the Plan).
TARRYTOWN, N.Y., Aug. 4, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) published positive detailed results from a Phase 3 trial that assessed the ability of REGEN-COV™ (casirivimab and imdevimab) to prevent COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial met its primary endpoint, reducing the risk of symptomatic infections by 81% (p<0.001), with a 93% reduction of symptomatic infections after the first week, and no dose-limiting toxicities observed.
CEDAR PARK, Texas, Aug. 4, 2021 /PRNewswire/ -- Bioidentical hormone replacement therapy, also known as BHRT, is rapidly gaining popularity for those that need to combat the physiological effects of low testosterone or low estrogen levels and is the newest service offering at Nova Vita Wellness Centers.
EMERYVILLE, Calif., Aug. 4, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the second quarter of 2021.
NORTH CHICAGO, Ill., Aug. 4, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that JAMA Dermatology has published 24-week results from the Phase 3b Heads Up study evaluating the efficacy and safety of RINVOQ® (upadacitinib, 30 mg, once daily) versus DUPIXENT® (dupilumab, 300 mg, every other week) – both as monotherapy treatments – in adults with moderate to severe atopic dermatitis who were candidates for systemic therapy.
PHILADELPHIA, Aug. 4, 2021 /PRNewswire/ -- In a proof-of-concept study, researchers at Children's Hospital of Philadelphia (CHOP) have created a coating that can be applied to endotracheal tubes and release antimicrobial peptides that target infectious bacteria with specificity. The innovation could reduce upper-airway bacterial inflammation during intubation, a situation that can lead to chronic inflammation and a condition called subglottic stenosis, the narrowing of the airway by an accumulation of scar tissue. The findings were published recently in the journal The Laryngoscope.